Focus: Globus Medical is a publicly-traded medtech company specializing in minimally-invasive surgical tools for spinal and orthopedic procedures, with $1.6B in FY2025 revenue and a Pennsylvania headquarters.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Hot — 177 jobs added in 30d
Net +136 (177 new, 41 removed). Aggressive expansion phase.
Ideal for clinical operations, regulatory affairs, or commercial talent seeking stable growth in surgical medtech; poor fit for traditional drug development careers.
Flagship minimally-invasive spinal fusion system dominating pipeline with multiple comparative effectiveness studies.
Help build intelligence for Globus Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Globus Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Allograft biologic product with applications across cervical, lumbar, and disc degeneration indications.
Artificial disc replacement technology representing next-generation motion-preservation approach to spinal surgery.
WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth - TradingView
WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth TradingView
8-K Filing: MASIMO CORP (MASI) (CIK 0000937556) — FORM 8-K
FORM 8-K
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat - TradingView
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat TradingView
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now - TradingView
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now TradingView
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges - FinancialContent
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges FinancialContent
8-K Filing: ACCURAY INC (ARAY) (CIK 0001138723) — EXHIBIT 99.1
EXHIBIT 99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo